GO:0030210 heparin proteoglycan biosynthetic process: Glycosaminoglycan Assembly Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030210 describes the biosynthesis of heparin proteoglycans, in which a heparin glycosaminoglycan chain is assembled on a core protein through a tetrasaccharide linker and extensively modified by sulfation and epimerization.
• Heparin proteoglycans are best characterized in mast cells, where they are stored in secretory granules and contribute to granule structure and protease regulation.
• Heparin and heparin-mimetic proteoglycans can activate platelets through PEAR1 and PI3Kbeta signaling, linking this biosynthetic pathway to thrombotic and cardiovascular biology.
• Heparanase, an endoglycosidase that cleaves heparan sulfate and heparin chains, is a key modifier of proteoglycan function and a target in cancer and inflammation research.
• Protein-glycan interactions mediated by heparin/heparan sulfate chains regulate growth factor presentation, matrix metalloproteinase localization, and cell signaling, making this pathway central to extracellular matrix biology.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes involved in heparin proteoglycan biosynthesis and their downstream functions.
Description
GO:0030210, heparin proteoglycan biosynthetic process, is a biological process term in the Gene Ontology that describes the chemical reactions and pathways leading to the formation of heparin proteoglycans. These molecules consist of a core protein covalently linked to a heparin glycosaminoglycan chain, which is built from repeating disaccharide units and extensively modified by sulfation and epimerization. Heparin proteoglycans are structurally related to heparan sulfate proteoglycans but are distinguished by a higher content of N-sulfate and O-sulfate groups, giving them unique biochemical properties. This pathway is of major interest because heparin and related glycosaminoglycans regulate a wide range of biological processes, including growth factor signaling, protease activity, and cell-matrix interactions. Heparin proteoglycans are most abundant in mast cells, where they are packaged into secretory granules and contribute to granule integrity and the storage of bioactive mediators. Beyond mast cells, heparan sulfate and heparin-like chains are present on cell surfaces and in the extracellular matrix, where they modulate the activity of numerous proteins, including matrix metalloproteinases and growth factors. The biosynthesis of these chains is therefore not merely a metabolic curiosity but a central determinant of tissue homeostasis and immune regulation. Dysregulation of heparin/heparan sulfate biosynthesis and turnover has been implicated in cancer, inflammation, and thrombosis. For example, heparanase, the enzyme that cleaves heparan sulfate and heparin chains, promotes tumor infiltration by CAR-redirected T lymphocytes and is considered a therapeutic target. Heparin and heparin proteoglycan-mimetics can activate platelets via PEAR1 and PI3Kbeta, directly linking this pathway to platelet biology and cardiovascular risk. Understanding GO:0030210 at the molecular level is thus essential for researchers in glycobiology, immunology, oncology, and drug development.
heparin proteoglycan biosynthetic process At A Glance
| GO ID | GO:0030210 |
|---|---|
| GO term | heparin proteoglycan biosynthetic process |
| Ontology | biological_process |
| Synonym | heparan sulfate biosynthetic process; heparin anabolism; heparin biosynthesis; heparin formation; heparin synthesis |
| Major function | Biosynthesis of heparin proteoglycans, including heparin chain assembly, sulfation, epimerization, and O-linked attachment to core proteins |
| Definition source | QuickGO definition based on published glycobiology literature |
| Related molecules | Heparin, heparan sulfate, core proteins, tetrasaccharide linker, sulfotransferases, epimerases |
| Cellular context | Mast cell secretory granules, extracellular matrix, cell surface proteoglycans |
| Disease relevance | Cancer, thrombosis, inflammation, and extracellular matrix remodeling |
What Is GO:0030210?
In simple terms, GO:0030210 describes how cells build heparin proteoglycans, which are composite molecules made of a protein core and a long, highly sulfated sugar chain called heparin. The heparin chain is composed of repeating disaccharide units of beta-(1,4)-N-acetyl-D-glucosamine and alpha-(1,4)-hexuronic acid, where the glucosamine can be sulfated or deacetylated on its amino group and sulfated on a hydroxyl group, and the hexuronic acid can be D-glucuronic acid or L-iduronic acid in sulfated or nonsulfated forms. Heparin is similar to heparan sulfate but contains more N-sulfate and O-sulfate groups. The chain is covalently attached to serine or threonine residues of the core protein through a tetrasaccharide linker sequence of xylose-galactose-galactose-glucuronate (O-linked). This process encompasses all the enzymatic steps required to synthesize, modify, and attach the heparin chain to the core protein.
Why Is heparin proteoglycan biosynthetic process Important in Cell Biology?
GO:0030210 is important because heparin proteoglycans and related heparan sulfate structures are key regulators of cell signaling, extracellular matrix organization, and immune cell function. Heparin-like chains bind and modulate growth factors, chemokines, and matrix metalloproteinases, thereby influencing processes such as angiogenesis, inflammation, and tumor progression. In mast cells, heparin proteoglycans are essential for the structure and function of secretory granules, which store histamine, proteases, and other mediators of allergic and inflammatory responses. Moreover, heparin and heparin-mimetic proteoglycans can directly activate platelets through PEAR1 and PI3Kbeta, implicating this pathway in thrombotic disorders and cardiovascular disease. The turnover of heparin/heparan sulfate chains by heparanase affects tumor infiltration by immune cells and is a target for anticancer therapy. Thus, understanding the biosynthesis of heparin proteoglycans provides mechanistic insight into diverse physiological and pathological processes and offers opportunities for therapeutic intervention.
• Heparin proteoglycans are major components of mast cell secretory granules and are required for granule integrity and mediator storage.
• Heparin and heparan sulfate chains regulate growth factor signaling and matrix metalloproteinase localization in the extracellular matrix.
• Heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kbeta, linking this pathway to thrombosis.
• Heparanase-mediated cleavage of heparan sulfate/heparin chains promotes tumor infiltration by CAR-redirected T lymphocytes.
• Heparanase is a validated therapeutic target in cancer and inflammation, underscoring the importance of proteoglycan turnover.
• Protein-glycan interactions mediated by heparin/heparan sulfate are emerging as druggable targets in multiple diseases.
• Heparin-binding growth factors can be protected and delivered using engineered protein delivery systems that mimic extracellular mechanisms.
• Fluorescence techniques enable real-time visualization of proteoglycan dynamics in developmental and cell biology contexts.
• Dysregulated glycosaminoglycan biosynthesis contributes to cancer progression, fibrosis, and inflammatory disorders.
• CRISPR-based models allow causal testing of genes in this pathway, accelerating target discovery.
What Happens During heparin proteoglycan biosynthetic process?
Core protein synthesis and tetrasaccharide linker assembly
In simple terms: First, the cell makes a core protein and attaches a short sugar linker to it.
The biosynthesis of heparin proteoglycans begins with the synthesis of a core protein, typically a serglycin-like proteoglycan in mast cells, which is translocated into the endoplasmic reticulum and Golgi apparatus. Specific serine or threonine residues on the core protein serve as attachment sites for glycosaminoglycan chains. A tetrasaccharide linker sequence composed of xylose-galactose-galactose-glucuronate is assembled on these residues by a series of glycosyltransferases. This linker serves as the primer for subsequent heparin chain elongation. The core protein and linker structure are essential for proper recognition by downstream enzymes and for the eventual formation of a functional proteoglycan.
Heparin chain elongation and polymerization
In simple terms: Next, the cell extends the linker into a long sugar chain made of repeating units.
After the tetrasaccharide linker is assembled, the heparin chain is elongated by the alternating addition of glucuronic acid and N-acetylglucosamine residues, forming the repeating disaccharide unit beta-(1,4)-N-acetyl-D-glucosamine-alpha-(1,4)-hexuronic acid. This polymerization step is catalyzed by glycosyltransferases that extend the chain processively. The elongating chain remains attached to the core protein and is progressively modified as it grows. The length and composition of the chain influence the final biochemical properties of the heparin proteoglycan, including its charge density and ability to interact with proteins.
N-deacetylation and N-sulfation of glucosamine residues
In simple terms: The sugar units are chemically modified by removing acetyl groups and adding sulfate groups.
During heparin biosynthesis, N-acetylglucosamine residues in the growing chain undergo N-deacetylation followed by N-sulfation, converting them to N-sulfoglucosamine units. This modification is a hallmark of heparin and distinguishes it from less sulfated heparan sulfate. The reaction is catalyzed by bifunctional enzymes with N-deacetylase and N-sulfotransferase activities. The resulting N-sulfate groups create binding sites for subsequent O-sulfation and epimerization reactions. The extent of N-sulfation directly affects the overall negative charge and protein-binding capacity of the heparin chain.
O-sulfation and uronic acid epimerization
In simple terms: Additional sulfate groups are added, and some sugar units are flipped into a different shape.
Following N-sulfation, the heparin chain undergoes O-sulfation at various positions, including C6 and C3 of glucosamine and C2 of uronic acid residues. These reactions are catalyzed by specific O-sulfotransferases and further increase the negative charge of the molecule. In parallel, some D-glucuronic acid residues are epimerized to L-iduronic acid by glucuronyl C5-epimerase. The combination of O-sulfation and epimerization generates the highly sulfated, structurally diverse heparin chain that is characteristic of mature heparin proteoglycans. This structural diversity underlies the ability of heparin to interact with a wide range of proteins, including growth factors and proteases.
Final processing, storage, and secretion
In simple terms: The finished proteoglycan is packaged into granules and can be released from the cell.
Once the heparin chain is fully modified, the mature heparin proteoglycan is transported to secretory granules in mast cells, where it is stored in a condensed form together with proteases and other mediators. The highly negative charge of heparin facilitates the packaging of positively charged granule components. Upon cell activation, the proteoglycan can be released into the extracellular space, where it participates in processes such as protease regulation, growth factor sequestration, and platelet activation. The turnover of heparin/heparan sulfate chains by heparanase further modulates the bioavailability of these molecules and their bound partners.
Key Genes Involved in GO:0030210 heparin proteoglycan biosynthetic process
The following genes and proteins are experimentally implicated in heparin/heparan sulfate biosynthesis, modification, or turnover, and are commonly studied in the context of GO:0030210.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Serglycin (SRGN) | Core protein for mast cell heparin proteoglycans | Mast cell granule formation and inflammatory mediator storage |
| Heparanase (HPSE) | Endoglycosidase that cleaves heparan sulfate/heparin chains | Tumor infiltration, CAR-T therapy, and cancer progression |
| PEAR1 | Platelet receptor activated by heparin proteoglycan-mimetics | Platelet activation and thrombosis research |
| PI3Kbeta (PIK3CB) | Signaling kinase downstream of PEAR1 | Platelet signaling and cardiovascular biology |
| MMP-2 (MMP2) | Matrix metalloproteinase that binds heparan sulfate | Extracellular matrix remodeling and cancer invasion |
| MMP-9 (MMP9) | Matrix metalloproteinase with heparin-binding properties | Inflammation and tumor microenvironment |
| VEGF (VEGFA) | Growth factor that binds heparin/heparan sulfate | Angiogenesis and vascular biology |
| FGF2 | Growth factor regulated by heparin/heparan sulfate | Cell proliferation and differentiation |
| EXT1 | Glycosyltransferase involved in heparan sulfate chain elongation | Heparan sulfate biosynthesis and developmental disorders |
| EXT2 | Glycosyltransferase involved in heparan sulfate chain elongation | Heparan sulfate biosynthesis and developmental disorders |
| NDST1 | N-deacetylase/N-sulfotransferase for heparan sulfate/heparin | Chain sulfation and protein binding |
| NDST2 | N-deacetylase/N-sulfotransferase in mast cells | Heparin biosynthesis and granule function |
| GLCE | Glucuronyl C5-epimerase | Uronic acid epimerization in heparin/heparan sulfate |
| HS2ST1 | Heparan sulfate 2-O-sulfotransferase | O-sulfation and ligand binding |
| HS6ST1 | Heparan sulfate 6-O-sulfotransferase | O-sulfation and signaling regulation |
| HS3ST1 | Heparan sulfate 3-O-sulfotransferase | Anticoagulant activity and protein interactions |
| SULF1 | Sulfatase that modifies heparan sulfate | Extracellular matrix remodeling and cancer |
| SULF2 | Sulfatase that modifies heparan sulfate | Growth factor signaling and tumor progression |
How Is heparin proteoglycan biosynthetic process Regulated?
The heparin proteoglycan biosynthetic process is regulated at multiple levels, including transcriptional control of core protein and biosynthetic enzyme genes, post-translational modification of enzymes, and availability of sulfate donors. In mast cells, the expression of serglycin and specific sulfotransferases is coordinated with granule biogenesis. The activity of heparanase, which degrades heparin/heparan sulfate chains, is regulated by proteolytic processing and pH, and its expression is elevated in many tumors. Heparin and heparin-mimetic proteoglycans can activate platelets through PEAR1 and PI3Kbeta, indicating that extracellular signals can feed back on proteoglycan function. Additionally, protein-glycan interactions in the extracellular matrix can modulate the presentation of growth factors and proteases, indirectly influencing the demand for heparin/heparan sulfate biosynthesis.
heparin proteoglycan biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HPSE | Cancer progression, metastasis, CAR-T infiltration | Knockout and overexpression in tumor cell lines |
| PEAR1 | Platelet activation, thrombosis | Point mutation and knockout in megakaryocyte/platelet models |
| SRGN | Mast cell granule defects, inflammation | Knockout in mast cell lines and primary mast cells |
| NDST2 | Impaired heparin biosynthesis, mast cell dysfunction | Knockout and knock-in in hematopoietic cells |
| MMP2/MMP9 | Extracellular matrix remodeling, cancer invasion | Knockout and tagged knock-in in fibroblasts and cancer cells |
Heparin proteoglycans in cancer and metastasis
Heparanase, the enzyme that cleaves heparan sulfate and heparin chains, promotes tumor infiltration by CAR-redirected T lymphocytes and is a target for anticancer therapy. Elevated heparanase expression is associated with tumor progression, metastasis, and poor prognosis in multiple cancers. The remodeling of heparan sulfate/heparin chains in the tumor microenvironment affects growth factor availability, angiogenesis, and immune cell infiltration. Therefore, genes involved in GO:0030210 and its turnover are actively investigated as therapeutic targets in oncology.
Thrombosis and platelet activation
Heparin and heparin proteoglycan-mimetics can activate platelets via PEAR1 and PI3Kbeta, directly linking this biosynthetic pathway to platelet biology and thrombotic risk. This mechanism is relevant to heparin-induced thrombocytopenia and other thrombotic disorders. Understanding how heparin proteoglycans and their mimetics interact with platelet receptors may inform the development of safer anticoagulant and antiplatelet therapies.
Inflammation and mast cell biology
Heparin proteoglycans are major constituents of mast cell secretory granules, where they contribute to granule structure and the storage of inflammatory mediators. Dysregulated mast cell function is implicated in allergy, asthma, and autoimmune diseases. The biosynthesis of heparin proteoglycans is therefore central to mast cell biology and inflammatory responses. Modulating this pathway could provide new strategies for treating mast cell-driven diseases.
Extracellular matrix remodeling and fibrosis
Heparan sulfate and heparin chains interact with matrix metalloproteinases and growth factors, influencing extracellular matrix turnover and fibrosis. Protein-glycan interactions are emerging as therapeutic targets in fibrotic and inflammatory diseases. Alterations in the biosynthesis or sulfation of these chains can affect tissue remodeling and repair.
From heparin proteoglycan biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HPSE affect tumor infiltration by CAR-T cells? | HPSE knockout in tumor cells or mouse models |
| Does PEAR1 mediate platelet activation by heparin mimetics? | PEAR1 point-mutation or knockout in platelet-like cells |
| Is serglycin required for mast cell granule formation? | SRGN knockout in mast cell lines |
| How does NDST2 sulfation activity affect heparin chain structure? | NDST2 knock-in with catalytic mutations |
| Can tagged core proteins be used to track heparin proteoglycan trafficking? | Knock-in of fluorescent or epitope tags on serglycin |
| Does overexpression of heparan sulfate sulfotransferases alter growth factor signaling? | Overexpression of HS6ST1 or HS3ST1 in mammalian cells |
How to Study the heparin proteoglycan biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Glycan composition and sulfation pattern | Characterizing heparin/heparan sulfate from cells |
| HPLC | Disaccharide composition and chain length | Assessing biosynthetic enzyme activity |
| Live-cell fluorescence imaging | Proteoglycan trafficking and secretion | Mast cell granule dynamics |
| Surface plasmon resonance | Binding affinity to growth factors/proteases | Protein-glycan interaction studies |
| RNA sequencing | Transcriptional changes in knockout models | Pathway analysis and target discovery |
| CRISPR knockout screens | Gene essentiality and pathway regulators | Functional genomics of glycosaminoglycan biosynthesis |
| Platelet aggregation assays | Platelet activation by heparin mimetics | Thrombosis research |
| CAR-T infiltration assays | Immune cell migration through matrix | Cancer immunotherapy studies |
Glycan analysis by mass spectrometry and chromatography
Mass spectrometry and high-performance liquid chromatography are used to determine the composition, sulfation pattern, and chain length of heparin/heparan sulfate isolated from cells or tissues. These methods provide direct biochemical evidence of biosynthetic enzyme activity and can be applied to knockout or knock-in models to assess the impact of specific genes on glycan structure.
Fluorescence imaging of proteoglycan dynamics
Fluorescence techniques, including live-cell imaging and fluorescent tagging of core proteins, allow visualization of proteoglycan trafficking and secretion in real time. These approaches are valuable for studying mast cell granule formation and the extracellular distribution of heparin proteoglycans.
Protein-glycan interaction assays
Binding assays, such as surface plasmon resonance and enzyme-linked immunosorbent assays, are used to measure interactions between heparin/heparan sulfate chains and proteins such as growth factors, proteases, and platelet receptors. These methods help define the functional consequences of altered biosynthesis.
CRISPR-based genetic screens and transcriptomics
CRISPR knockout screens combined with RNA sequencing can identify genes that regulate heparin proteoglycan biosynthesis and downstream signaling. Transcriptomic profiling of knockout or overexpression models reveals pathway-level changes and candidate therapeutic targets.
How CRISPR Can Be Used to Study GO:0030210 heparin proteoglycan biosynthetic process
Knockout
CRISPR knockout of genes such as HPSE, SRGN, or NDST2 allows researchers to test their causal role in heparin proteoglycan biosynthesis and downstream functions. For example, HPSE knockout can reduce tumor infiltration by CAR-T cells, providing direct evidence for its role in matrix remodeling. Knockout models are also used to assess the impact of specific enzymes on glycan structure and mast cell granule formation.
Point Mutation
Point mutations can be introduced into catalytic residues or regulatory sites of biosynthetic enzymes to dissect their specific activities without completely abolishing protein expression. For instance, point mutations in NDST2 can separate its N-deacetylase and N-sulfotransferase activities, revealing their individual contributions to heparin chain modification. Similarly, point mutations in PEAR1 can identify residues required for platelet activation by heparin mimetics.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or reporter genes into endogenous loci enables tracking of core proteins and biosynthetic enzymes in their native context. Tagged serglycin, for example, can be used to follow heparin proteoglycan trafficking to secretory granules. Knock-in of disease-associated mutations can also model human disorders linked to glycosaminoglycan biosynthesis.
Overexpression
Overexpression of biosynthetic enzymes or core proteins can amplify pathway output and facilitate biochemical analysis of heparin/heparan sulfate chains. Overexpression of sulfotransferases such as HS6ST1 or HS3ST1 can alter the sulfation pattern and protein-binding properties of the chains, providing insight into structure-function relationships. Overexpression models are also useful for testing the effects of excess heparin proteoglycans on cell signaling and platelet activation.
How EDITGENE Supports heparin proteoglycan biosynthetic process Research
Researchers studying heparin proteoglycan biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in glycan assembly, modification, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations, enabling rigorous functional validation of genes implicated in GO:0030210.
Contact EDITGENE today to design your custom CRISPR model for heparin proteoglycan biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ANGPT1 Knockout HEK293 Cell Line | EDJ-KQ1201 | Human | 284 | Details Get a Quote |
| GLCE Knockout HEK293 Cell Line | EDJ-KQ3056 | Human | 26035 | Details Get a Quote |
| NDST1 Knockout HEK293 Cell Line | EDJ-KQ4951 | Human | 3340 | Details Get a Quote |
| NDST2 Knockout HEK293 Cell Line | EDJ-KQ6262 | Human | 8509 | Details Get a Quote |
| NDST3 Knockout HEK293 Cell Line | EDJ-KQ6555 | Human | 9348 | Details Get a Quote |
| SLC10A7 Knockout HEK293 Cell Line | EDJ-KQ9965 | Human | 84068 | Details Get a Quote |
| CSGALNACT1 Knockout HEK293 Cell Line | EDJ-KQ13013 | Human | 55790 | Details Get a Quote |
| NDST2 Knockout A-549 Cell Line | EDJ-KQ30145 | Human | 8509 | Details Get a Quote |
| NDST2 Knockout HeLa Cell Line | EDJ-KQ30147 | Human | 8509 | Details Get a Quote |
| GLCE Knockout A-549 Cell Line | EDJ-KQ24313 | Human | 26035 | Details Get a Quote |
| GLCE Knockout HCT 116 Cell Line | EDJ-KQ24314 | Human | 26035 | Details Get a Quote |
| GLCE Knockout HeLa Cell Line | EDJ-KQ24315 | Human | 26035 | Details Get a Quote |
| NDST1 Knockout HeLa Cell Line | EDJ-KQ26602 | Human | 3340 | Details Get a Quote |
| NDST1 Knockout A-549 Cell Line | EDJ-KQ27817 | Human | 3340 | Details Get a Quote |
| NDST1 Knockout HCT 116 Cell Line | EDJ-KQ27818 | Human | 3340 | Details Get a Quote |
Displaying Records 1 To 15 Of 32 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About heparin proteoglycan biosynthetic process
What is GO:0030210?
GO:0030210 is the Gene Ontology term for heparin proteoglycan biosynthetic process, which describes the chemical reactions and pathways that build heparin proteoglycans, including chain assembly, sulfation, epimerization, and attachment to a core protein.
What is heparin proteoglycan biosynthetic process?
It is the biological process by which cells synthesize heparin proteoglycans, molecules composed of a core protein linked to a highly sulfated heparin glycosaminoglycan chain.
What genes are involved in heparin proteoglycan biosynthetic process?
Key genes include SRGN (serglycin), HPSE (heparanase), NDST1, NDST2, EXT1, EXT2, GLCE, HS2ST1, HS6ST1, HS3ST1, and PEAR1, among others.
Where does heparin proteoglycan biosynthesis occur?
It occurs primarily in the endoplasmic reticulum and Golgi apparatus of cells, especially mast cells, where the mature proteoglycan is stored in secretory granules.
What is the difference between heparin and heparan sulfate?
Heparin contains more N-sulfate and O-sulfate groups than heparan sulfate, giving it a higher negative charge and distinct protein-binding properties.
How is heparin proteoglycan biosynthesis regulated?
It is regulated by transcriptional control of core protein and enzyme genes, post-translational modifications, sulfate donor availability, and extracellular signals such as platelet receptor activation.
What diseases are associated with heparin proteoglycan biosynthesis?
Dysregulation is linked to cancer, thrombosis, inflammation, and extracellular matrix remodeling disorders.
How can CRISPR be used to study heparin proteoglycan biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes involved in the pathway and their downstream effects.
What methods are used to study heparin proteoglycan biosynthesis?
Common methods include mass spectrometry, HPLC, fluorescence imaging, protein-glycan binding assays, RNA sequencing, and CRISPR screens.
Why is heparanase important in this pathway?
Heparanase cleaves heparan sulfate and heparin chains, modulating their function and influencing tumor infiltration, inflammation, and matrix remodeling.
Conclusion
GO:0030210, heparin proteoglycan biosynthetic process, encompasses the enzymatic steps that build one of the most highly sulfated glycoconjugates in biology. Its products regulate mast cell granule function, growth factor signaling, platelet activation, and extracellular matrix remodeling, making the pathway relevant to cancer, thrombosis, and inflammation. Continued research using CRISPR-based models and advanced glycan analytics will clarify how individual genes contribute to pathway output and how these insights can be translated into therapeutic strategies. EDITGENE supports this research by providing customizable knockout, point-mutation, knock-in, overexpression, and library screening services, enabling precise functional dissection of heparin proteoglycan biosynthesis and its role in human disease.
References
- 1. Caruana I et al.. 2015. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.. Nat Med 21(5):524-9 PMID: 25849134
- 2. Lindahl U et al.. 2020. Heparanase - Discovery and Targets.. Adv Exp Med Biol 1221:61-69 PMID: 32274706
- 3. Kardeby C et al.. 2023. Heparin and heparin proteoglycan-mimetics activate platelets via PEAR1 and PI3Kβ.. J Thromb Haemost 21(1):101-116 PMID: 36695374
- 4. Rönnberg E et al.. 2012. Mast cell proteoglycans.. J Histochem Cytochem 60(12):950-62 PMID: 22899859
- 5. Van Doren SR et al.. 2017. Peripheral membrane associations of matrix metalloproteinases.. Biochim Biophys Acta Mol Cell Res 1864(11 Pt A):1964-1973 PMID: 28442379
- 6. Rek A et al.. 2009. Therapeutically targeting protein-glycan interactions.. Br J Pharmacol 157(5):686-94 PMID: 19371327
- 7. Silva C et al.. 2017. Design of protein delivery systems by mimicking extracellular mechanisms for protection of growth factors.. Acta Biomater 63:283-293 PMID: 28864252
- 8. Veerapathiran S et al.. 2018. Fluorescence techniques in developmental biology.. J Biosci 43(3):541-553 PMID: 30002271
